2629-59-6

Basic information

• Product Name: S-ETHYL-L-CYSTEINE
• Synonyms: H-CYS(ET)-OH;S-ETHYL-L-CYSTEINE;S-ethyl-L-cysteine crystalline;5-ETHYL-L-CYSTEINE;3-(Ethylthio)alanine;Aids034431;Aids-034431;Nsc49244
• CAS NO: 2629-59-6
• Molecular Formula: C5H11NO2S
• Molecular Weight: 149.21
• EINECS: 220-106-2
• Product Categories: A - H;Amino Acids;Modified Amino Acids
• Mol File: 2629-59-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 260°C
• Boiling Point: 289.2°Cat760mmHg
• Flash Point: 128.7°C
• Appearance: /
• Density: 1.206g/cm³
• Vapor Pressure: 0.00908mmHg at 25°C
• Refractive Index: 1.504
• Storage Temp.: −20°C
• PKA: pK1:2.03(+1);pK2:8.60(0) (25°C,μ=0.1)
• CAS DataBase Reference: S-ETHYL-L-CYSTEINE(CAS DataBase Reference)
• NIST Chemistry Reference: S-ETHYL-L-CYSTEINE(2629-59-6)
• EPA Substance Registry System: S-ETHYL-L-CYSTEINE(2629-59-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 2629-59-6(Hazardous Substances Data)

Usage

General Description

S-Ethyl-L-cysteine is a naturally occurring compound that is commonly found in a variety of foods, particularly those from the allium family, such as garlic and onions. It is a derivative of the amino acid L-cysteine, and is known for its potential health benefits, including antioxidant properties and potential protective effects against certain types of cancer. S-Ethyl-L-cysteine has also been investigated for its potential to reduce the toxic effects of alcohol and protect against liver damage. Additionally, it has been studied for its potential to lower cholesterol levels and improve cardiovascular health. Overall, S-Ethyl-L-cysteine is a promising compound with various potential health benefits and is a subject of ongoing research and study.

InChI:InChI=1/C5H11NO2S/c1-2-6-4(3-9)5(7)8/h4,6,9H,2-3H2,1H3,(H,7,8)/t4-/m0/s1

Upstream product

• 64-67-5 diethyl sulfate 
• 52-90-4 L-Cysteine 
• 31386-36-4 S-Ethyl-N-acetyl-L-cysteine 
• 52-89-1 l-cysteine hydrochloride 
• 75-03-6 ethyl iodide 
• 56-45-1 L-serin 
• 75-08-1 ethanethiol 
• 74-96-4 ethyl bromide 
• 2731-73-9 2-amino-3-chloropropanoic acid 

Downstream Products

• 93429-15-3 N-(N-acetyl-sulfanilyl)-S-ethyl-L-cysteine 
• 624-89-5 Ethyl methyl sulfide 
• 75-08-1 ethanethiol 
• 16947-82-3 Boc-(S-ethyl)Cys-OH 
• 127-17-3 2-oxo-propionic acid 
• 97019-32-4 N-<4-Sulfanilamino-benzol-sulfonyl-(1)>-S-ethyl-L-cystein 
• 91431-26-4 S-ethyl-N-sulfanilyl-L-cysteine 
• 66960-15-4 {(S)-1-[((R)-1-Carbamoyl-2-ethylsulfanyl-ethyl)-methyl-carbamoyl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 88389-32-6 N-(2-benzyl-3-mercaptopropanoyl)-S-ethyl-L-cysteine 
• 156792-17-5 (R)-2-((S)-2-Acetylsulfanylmethyl-3-phenyl-propionylamino)-3-ethylsulfanyl-propionic acid ethyl ester 
• 33672-79-6 ethylsulfanyl-acetaldehyde 
• 75-07-0 acetaldehyde 
• 302-72-7 rac-Ala-OH 
• 17795-08-3 S-ethyl-L-cysteine sulfoxide 

Relevant articles and documents

Influence of Sulfoxide Group Placement on Polypeptide Conformational Stability

The synthesis of a homologous series containing five new nonionic sulfoxide containing polypeptides was described. Sulfoxide groups bestowed water solubility for all homologues, which allowed their use as a model for study of helix-coil transitions in water while avoiding contributions from charged groups or phase separation. Polypeptides were found to adopt chain conformations in water that were dependent on distance of sulfoxides from chain backbones, overall side-chain lengths, and solvent. These results allow preparation of polypeptide segments with different chain conformations without changing chemical functionality for potential use in structural studies and functional applications.

A step-by-step crystallization for preparing thio alkyl/alkenyl cysteine sulfoxide method

The invention discloses a method for preparing thioalkyl/alkenyl cysteine sulfoxide by fractional crystallization, belonging to the technical field of compound preparation. The method comprises the following steps: adding cysteine or cysteine salts, a sodium hydroxide solution and an R group (alkyl or alkenyl)-derived material into absolute ethanol in sequence for reaction to synthesize coarse ACSs, re-crystallizing ACSs, purifying, oxidizing to form ACSOs, and fractionally crystallizing to obtain natural dextrorotatory ACSOs, wherein the R group-derived material is replaced to synthesize different types of ACSOs in allium; enantiomers in racemes are separated by adopting the fractional crystallization method to obtain natural dextrorotatory ACSOs with optical activity. Compared with a conventional extraction method, the method has the characteristics that the yield and the purity are high, a conventional complicated extraction process is avoided, the product has the optical activity, and the physical property is close to that of natural extract; the product is used in the fields of health products, pharmaceuticals and the like, the effects of resisting bacteria and cancers, reducing blood fat and the like of ACSOs are brought into play, or the product serves as an intermediate such as an active ingredient-diallyl thiosulfinate for synthesizing allium.

Method Of Synthesizing S-Allyl-Cysteine Analogues And Their Therapeutic Application In Treating Myocardial Infarction

A pharmaceutical composition and methods of producing and application of the composition for treating myocardial infarction of a subject are disclosed. The pharmaceutical composition comprises a therapeutically effective amount of at least one synthesized compound selected from the group consisting of SEC, SPC, SBC, SPEC, SAC, SAMC, and SPRC, and a pharmaceutically acceptable carrier.